FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3191846128> ?p ?o ?g. }

• W3191846128 endingPage "2369" @default.
• W3191846128 startingPage "2353" @default.
• W3191846128 abstract "The administration of systemic corticosteroids is a key strategy for improving COVID-19 outcomes. However, evidence is lacking on combination therapies of antiviral agents and systemic corticosteroids. The objective of this study was to investigate the efficacy and safety of the combination therapy of favipiravir and methylprednisolone in preventing respiratory failure progression in patients with COVID-19 and non-critical respiratory failure.We conducted a multicenter, open-label, single-arm phase II study. The patients received favipiravir 3600 mg on the first day, followed by 1600 mg for a total of 10-14 days. Methylprednisolone was administered intravenously at 1 mg/ideal body weight (IBW)/day from days 1 to 5, followed by 0.5 mg/IBW/day from days 6 to 10 if clinically indicated. The primary endpoint was the proportion of patients requiring mechanical ventilation (MV) (including noninvasive positive pressure ventilation) or those who met the criteria for tracheal intubation within 14 days of the study treatment initiation (MVCTI-14).Sixty-nine patients were enrolled and underwent the study treatment. Of them, the MVCTI-14 proportion was 29.2% (90% confidence interval 20.1-39.9, p = 0.200). The proportion of patients who required MV or who died within 30 days was 26.2%, and 30-day mortality was 4.9%. The most significant risk factor for MVCTI-14 was a smoking history (odds ratio 4.1, 95% confidence interval 1.2-14.2). The most common grade 3-4 treatment-related adverse event was hyperglycemia, which was observed in 21.7%.The MVCTI-14 proportion did not reach a favorable level in the clinical trial setting with the threshold of 35%. However, the proportion of MV or death within 30 days was 26.6%, which might be close to the findings (28.1%) of the RECOVERY trial, which showed the efficacy of dexamethasone for patients with COVID-19 and non-critical respiratory failure. Further evaluation of this combination therapy is needed.Japan Registry of Clinical Trials (jRCT) identifier jRCTs041200025." @default.
• W3191846128 created "2021-08-16" @default.
• W3191846128 creator A5006534529 @default.
• W3191846128 creator A5011755925 @default.
• W3191846128 creator A5016286590 @default.
• W3191846128 creator A5024610790 @default.
• W3191846128 creator A5025872899 @default.
• W3191846128 creator A5033357301 @default.
• W3191846128 creator A5034173750 @default.
• W3191846128 creator A5034180464 @default.
• W3191846128 creator A5036577393 @default.
• W3191846128 creator A5038162416 @default.
• W3191846128 creator A5040492584 @default.
• W3191846128 creator A5043796518 @default.
• W3191846128 creator A5049715323 @default.
• W3191846128 creator A5054408940 @default.
• W3191846128 creator A5066707685 @default.
• W3191846128 creator A5067422608 @default.
• W3191846128 creator A5071159100 @default.
• W3191846128 creator A5076970278 @default.
• W3191846128 creator A5086830418 @default.
• W3191846128 date "2021-08-08" @default.
• W3191846128 modified "2023-10-16" @default.
• W3191846128 title "Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure" @default.
• W3191846128 cites W1693418437 @default.
• W3191846128 cites W1693866076 @default.
• W3191846128 cites W2060514161 @default.
• W3191846128 cites W2106024919 @default.
• W3191846128 cites W2138274210 @default.
• W3191846128 cites W2142413409 @default.
• W3191846128 cites W2415688627 @default.
• W3191846128 cites W3004626187 @default.
• W3191846128 cites W3011610993 @default.
• W3191846128 cites W3011779988 @default.
• W3191846128 cites W3012421327 @default.
• W3191846128 cites W3024079853 @default.
• W3191846128 cites W3027630905 @default.
• W3191846128 cites W3033163537 @default.
• W3191846128 cites W3048223030 @default.
• W3191846128 cites W3048633295 @default.
• W3191846128 cites W3080718665 @default.
• W3191846128 cites W3082355253 @default.
• W3191846128 cites W3087214787 @default.
• W3191846128 cites W3087465356 @default.
• W3191846128 cites W3092285496 @default.
• W3191846128 cites W3101243097 @default.
• W3191846128 cites W3110379274 @default.
• W3191846128 cites W3112066809 @default.
• W3191846128 cites W3112902030 @default.
• W3191846128 cites W3114096059 @default.
• W3191846128 cites W3124006382 @default.
• W3191846128 cites W3129877211 @default.
• W3191846128 cites W3130126061 @default.
• W3191846128 cites W3133932534 @default.
• W3191846128 cites W3138442116 @default.
• W3191846128 cites W3150187987 @default.
• W3191846128 cites W4210642183 @default.
• W3191846128 doi "https://doi.org/10.1007/s40121-021-00512-9" @default.
• W3191846128 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8349598" @default.
• W3191846128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34368914" @default.
• W3191846128 hasPublicationYear "2021" @default.
• W3191846128 type Work @default.
• W3191846128 sameAs 3191846128 @default.
• W3191846128 citedByCount "5" @default.
• W3191846128 countsByYear W31918461282022 @default.
• W3191846128 countsByYear W31918461282023 @default.
• W3191846128 crossrefType "journal-article" @default.
• W3191846128 hasAuthorship W3191846128A5006534529 @default.
• W3191846128 hasAuthorship W3191846128A5011755925 @default.
• W3191846128 hasAuthorship W3191846128A5016286590 @default.
• W3191846128 hasAuthorship W3191846128A5024610790 @default.
• W3191846128 hasAuthorship W3191846128A5025872899 @default.
• W3191846128 hasAuthorship W3191846128A5033357301 @default.
• W3191846128 hasAuthorship W3191846128A5034173750 @default.
• W3191846128 hasAuthorship W3191846128A5034180464 @default.
• W3191846128 hasAuthorship W3191846128A5036577393 @default.
• W3191846128 hasAuthorship W3191846128A5038162416 @default.
• W3191846128 hasAuthorship W3191846128A5040492584 @default.
• W3191846128 hasAuthorship W3191846128A5043796518 @default.
• W3191846128 hasAuthorship W3191846128A5049715323 @default.
• W3191846128 hasAuthorship W3191846128A5054408940 @default.
• W3191846128 hasAuthorship W3191846128A5066707685 @default.
• W3191846128 hasAuthorship W3191846128A5067422608 @default.
• W3191846128 hasAuthorship W3191846128A5071159100 @default.
• W3191846128 hasAuthorship W3191846128A5076970278 @default.
• W3191846128 hasAuthorship W3191846128A5086830418 @default.
• W3191846128 hasBestOaLocation W31918461281 @default.
• W3191846128 hasConcept C126322002 @default.
• W3191846128 hasConcept C156957248 @default.
• W3191846128 hasConcept C197934379 @default.
• W3191846128 hasConcept C203092338 @default.
• W3191846128 hasConcept C2776888751 @default.
• W3191846128 hasConcept C2777080012 @default.
• W3191846128 hasConcept C2779134260 @default.
• W3191846128 hasConcept C2779772310 @default.
• W3191846128 hasConcept C2780372218 @default.
• W3191846128 hasConcept C3008058167 @default.
• W3191846128 hasConcept C42219234 @default.

• next